Analyst Rating Update on Galena Biopharma (GALE)

Galena Biopharma (NASDAQ:GALE) : 5 analysts are covering Galena Biopharma (NASDAQ:GALE) and their average rating on the stock is 1.2, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Galena Biopharma (NASDAQ:GALE) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.

Galena Biopharma (NASDAQ:GALE) : 5 investment research analysts covering Galena Biopharma (NASDAQ:GALE) have an average price target of $3.9 for the near short term. The highest target price given by the Brokerage Firm to the stock is $5 and the lowest target is $2 for the short term. Analysts expect the variance to be within $1.25 of the average price.

For the current week, the company shares have a recommendation consensus of Buy.

Galena Biopharma (NASDAQ:GALE): stock turned positive on Tuesday. Though the stock opened at $2.05, the bulls momentum made the stock top out at $2.12 level for the day. The stock recorded a low of $2.01 and closed the trading day at $2.03, in the green by 1.00%. The total traded volume for the day was 1,956,621. The stock had closed at $2.01 in the previous days trading.

In an insider trading activity, The Securities and Exchange Commission has divulged that Dunlap Ryan, officer (Former Chief Financial Officer) of Galena Biopharma, Inc., had unloaded 126,875 shares at an average price of $2.18 in a transaction dated on June 1, 2016. The total value of the transaction was worth $276,588.

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug, Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *